14 stories found
Shareholders are suing Novo Nordisk, alleging the company misled the market regarding the tolerability of its next-generation weight-loss drug, CagriSema, following disappointing clinical trial results.
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
Cagrisema viser et lavere vægttab end Eli Lillys aktive stof tirzepatid i et nyt studie. Novo-aktien falder til laveste niveau i fem år.
Novo Nordisk is reportedly facing a shareholder lawsuit that accuses the company of fraud related to its CagriSema trial.
Novo's stumbles burnish Lilly's widening lead in weight-loss drugs Reuters
Shares of Novo Nordisk, owner of Wegovy and Ozempic, fell sharply after its highly anticipated next-generation weight-loss drug, CagriSema, failed to meet investor expectations in testing, leading it to be branded 'obsolete'.
Once-a-week injection achieved weight loss of 23%, which is lower than some existing treatments
Novo Nordisk's stock dropped significantly after new data showed its experimental weight-loss drug Cagrisema was less effective than Eli Lilly's tirzepatide.
Barclays slashes sales forecasts for Novo's CagriSema by more than 80% Reuters
Doustdar tror, at Cagrisema bliver det bedste på markedet. Nye data viser højere vægttab med et andet middel.
Novo Nordisk's CEO Says Still 'Incredibly Optimistic' About CagriSema TradingView